Nephrogene

ACEI_ARB after TX

Response to Opelz et al. J Am Soc Nephrol 2006, 17:3257-62.

TABLES

FIGURES

Webtable 1
Associations of ACEI/ARB use and patient death in the four different strategies of model selection. Variables that were identified as confounder were included into the multivariate analysis. All predicting variables with the exception of recipient age and year of first renal replacement therapy were used as time dependent covariates in the Cox regression analysis.

Webfigure 1a
Screenshot of all variables in the relational database.
Webfigure 1b
Visual description of events within the first three months after first transplantation.

Webtable 2
Associations of ACEI/ARB use and graft failure in the four different approaches to model building. Variables that were identified as confounders were included into the multivariate analysis. All predicting variables with the exception of donor age, BCAR and CAN were used as time dependent covariates in the Cox regression analysis.

Webfigure 2a 2b 2c 2d
Graphical example of time dependent propensity scores of four representative patients.

Webtable 3a
Modification of the hazard ratio (HR) of ACEI/ARB use for death by potential confounding variables. Those variables that changed the HR of ACEI/ARB use by more than 10 % if omitted from a bivariable model involving ACEI/ARB use and the potential confounder were included in a ‘multivariable model adjusted for variables identified as confounders’ (see table 2 bottom).
Webtable 3b
Modification of the hazard ratio (HR) of ACEI/ARB use for graft failure by potential confounding variables. Those variables that changed the HR of ACEI/ARB use by more than 10% if omitted from a bivariable model involving ACEI/ARB use and the potential confounder were included in a ‘multivariable model adjusted for variables identified as confounders’ (see table 3 bottom).

Webfigure 3a
Duration of ACEI/ARB use as percentage of follow up time. The majority of subjects either received (31.4 %) or did not receive (38.5 %) ACEI/ARB during the whole follow up period.
The remaining 30.1 % of patients received ACEI/ARB therapy for equally distributed variable times of follow up.
Webfigure 3b
Cumulative incidence of ACEI or ARB medication over time.

Webfigure 4
Cumulative incidence of other (non-ACEI/ARB) antihypertensive drugs over time.

Webfigure 5
Scaled Schoenfeld residuals (test of proportional hazards assumption) for the patient survival model with confounding factors heart disease, vascular disease and the number of antihypertensive drugs (slope, p = 0.44).

Webfigure 6
Scaled Schoenfeld residuals (test of proportional hazards assumption) for the graft survival model with confounding factors heart disease, vascular disease, cholesterol, hemoglobin and the number of antihypertensive drugs (slope, p = 0.68).

TABLES		FIGURES
	Webtable 1 Associations of ACEI/ARB use and patient death in the four different strategies of model selection. Variables that were identified as confounder were included into the multivariate analysis. All predicting variables with the exception of recipient age and year of first renal replacement therapy were used as time dependent covariates in the Cox regression analysis.		Webfigure 1a Screenshot of all variables in the relational database. Webfigure 1b Visual description of events within the first three months after first transplantation.
	Webtable 2 Associations of ACEI/ARB use and graft failure in the four different approaches to model building. Variables that were identified as confounders were included into the multivariate analysis. All predicting variables with the exception of donor age, BCAR and CAN were used as time dependent covariates in the Cox regression analysis.		Webfigure 2a 2b 2c 2d Graphical example of time dependent propensity scores of four representative patients.
	Webtable 3a Modification of the hazard ratio (HR) of ACEI/ARB use for death by potential confounding variables. Those variables that changed the HR of ACEI/ARB use by more than 10 % if omitted from a bivariable model involving ACEI/ARB use and the potential confounder were included in a ‘multivariable model adjusted for variables identified as confounders’ (see table 2 bottom). Webtable 3b Modification of the hazard ratio (HR) of ACEI/ARB use for graft failure by potential confounding variables. Those variables that changed the HR of ACEI/ARB use by more than 10% if omitted from a bivariable model involving ACEI/ARB use and the potential confounder were included in a ‘multivariable model adjusted for variables identified as confounders’ (see table 3 bottom).		Webfigure 3a Duration of ACEI/ARB use as percentage of follow up time. The majority of subjects either received (31.4 %) or did not receive (38.5 %) ACEI/ARB during the whole follow up period. The remaining 30.1 % of patients received ACEI/ARB therapy for equally distributed variable times of follow up. Webfigure 3b Cumulative incidence of ACEI or ARB medication over time.
			Webfigure 4 Cumulative incidence of other (non-ACEI/ARB) antihypertensive drugs over time.
			Webfigure 5 Scaled Schoenfeld residuals (test of proportional hazards assumption) for the patient survival model with confounding factors heart disease, vascular disease and the number of antihypertensive drugs (slope, p = 0.44).
			Webfigure 6 Scaled Schoenfeld residuals (test of proportional hazards assumption) for the graft survival model with confounding factors heart disease, vascular disease, cholesterol, hemoglobin and the number of antihypertensive drugs (slope, p = 0.68).